These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 20963563

  • 1. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
    Hong JW, Lee MK, Kim SH, Lee EJ.
    Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
    [Abstract] [Full Text] [Related]

  • 2. [Hyperprolactinemia in patients with non-functioning adenoma: analysis of 85 patients treated by transsphenoidal operation].
    Saitoh Y, Mori S, Arita N, Hayakawa T, Mogami H, Oku Y, Onishi T, Uozumi T.
    No Shinkei Geka; 1987 Nov; 15(11):1175-9. PubMed ID: 3437926
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic evaluation of hyperprolactinemia.
    Biller BM.
    J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
    [Abstract] [Full Text] [Related]

  • 4. Clinical practice. Prolactinoma.
    Schlechte JA.
    N Engl J Med; 2003 Nov 20; 349(21):2035-41. PubMed ID: 14627789
    [No Abstract] [Full Text] [Related]

  • 5. Galactorrhea may be clue to serious problems. Patients deserve a thorough workup.
    Whitman-Elia GF, Windham NQ.
    Postgrad Med; 2000 Jun 20; 107(7):165-8, 171. PubMed ID: 10887453
    [Abstract] [Full Text] [Related]

  • 6. Lack of tumor reduction in hyperprolactinemic women with extrasellar macroadenomas treated with bromocriptine.
    Boulanger CM, Mashchak CA, Chang RJ.
    Fertil Steril; 1985 Oct 20; 44(4):532-5. PubMed ID: 4054327
    [Abstract] [Full Text] [Related]

  • 7. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V, Raftopoulos C, Maiter D.
    Eur J Endocrinol; 2012 May 20; 166(5):779-86. PubMed ID: 22301915
    [Abstract] [Full Text] [Related]

  • 8. [Current diagnosis and treatment of hyperprolactinemia].
    Melgar V, Espinosa E, Sosa E, Rangel MJ, Cuenca D, Ramírez C, Mercado M.
    Rev Med Inst Mex Seguro Soc; 2016 May 20; 54(1):111-21. PubMed ID: 26820213
    [Abstract] [Full Text] [Related]

  • 9. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
    Harms E, Siggelkow H, Buchfelder M, Saeger W, Hüfner M.
    Dtsch Med Wochenschr; 2003 Mar 28; 128(13):667-70. PubMed ID: 12660899
    [Abstract] [Full Text] [Related]

  • 10. The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients.
    Huan C, Cui G, Ren Z.
    Pak J Pharm Sci; 2015 Mar 28; 28(2 Suppl):713-8. PubMed ID: 25796163
    [Abstract] [Full Text] [Related]

  • 11. Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.
    Behan LA, O'Sullivan EP, Glynn N, Woods C, Crowley RK, Tun TK, Smith D, Thompson CJ, Agha A.
    J Endocrinol Invest; 2013 Mar 28; 36(7):508-14. PubMed ID: 23385474
    [Abstract] [Full Text] [Related]

  • 12. Two-step development of a pituitary adenoma: from hyperprolactinemic syndrome to Cushing's disease.
    Gheri RG, Boddi W, Ammannati F, Olivotto J, Nozzoli C, Franchi A, Bordi L, Luisi ML, Mennonna P.
    J Endocrinol Invest; 1997 Apr 28; 20(4):240-4. PubMed ID: 9211134
    [Abstract] [Full Text] [Related]

  • 13. Nonfunctioning pituitary macroadenoma presenting with mild hyperprolactinemia and amenorrhea.
    Hansen KA, Tho SP, Gomez F, McDonough PG.
    Fertil Steril; 1999 Oct 28; 72(4):663-5. PubMed ID: 10521106
    [Abstract] [Full Text] [Related]

  • 14. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
    Heneghan LJ, Tsang A, Dimino C, Khandji AG, Panigrahi SK, Page-Wilson G.
    J Clin Endocrinol Metab; 2024 Jan 18; 109(2):e667-e674. PubMed ID: 37715962
    [Abstract] [Full Text] [Related]

  • 15. Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma.
    Hage C, Salvatori R.
    J Clin Endocrinol Metab; 2020 Dec 01; 105(12):. PubMed ID: 32930718
    [Abstract] [Full Text] [Related]

  • 16. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK, Vance ML, Boulos PT, Laws ER.
    Pituitary; 2005 Dec 01; 8(1):53-60. PubMed ID: 16411069
    [Abstract] [Full Text] [Related]

  • 17. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
    Vilar L, Naves LA, Freitas MC, Lima M, Canadas V, Albuquerque JL, Lyra R, Azevedo MF, Casulari LA.
    Minerva Endocrinol; 2007 Jun 01; 32(2):79-86. PubMed ID: 17557033
    [Abstract] [Full Text] [Related]

  • 18. [The best approach to treat prolactinoma].
    Zárate A, Saucedo R, Basurto L.
    Gac Med Mex; 2004 Jun 01; 140(5):567-9. PubMed ID: 15559242
    [Abstract] [Full Text] [Related]

  • 19. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases.
    Eren E, Yapıcı Ş, Çakır ED, Ceylan LA, Sağlam H, Tarım Ö.
    J Clin Res Pediatr Endocrinol; 2011 Jun 01; 3(2):65-9. PubMed ID: 21750634
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis and treatment of pituitary adenomas.
    Chanson P, Salenave S.
    Minerva Endocrinol; 2004 Dec 01; 29(4):241-75. PubMed ID: 15765032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.